# Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

> **NCT06190249** · PHASE1 · WITHDRAWN · sponsor: **James Isaacs, MD**

## Conditions studied

- Stage IIIB Melanoma
- Stage IIIC Melanoma
- Stage IIID Melanoma

## Interventions

- **BIOLOGICAL:** LN-144
- **DRUG:** Cyclophosphamide
- **DRUG:** Mesna
- **DRUG:** Fludarabine
- **BIOLOGICAL:** Interleukin-2 (IL-2)
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT06190249
- **Lead sponsor:** James Isaacs, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-12-02
- **Primary completion:** 2028-01
- **Final completion:** 2028-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Iovance withdrew support due to length of time required to meet accrual goal.
- **Last updated:** 2025-06-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06190249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06190249, "Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06190249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*